OpenEvidence
$12Bpaper valuation
// OVERVIEW
OpenEvidence is a $12 billion medical AI company that nobody outside venture capital and hospital procurement committees has heard of — which tells you everything about whether it is solving a problem doctors asked for or a problem AI needed a use case to justify. The company builds clinical decision support tools that parse medical literature and generate evidence summaries for physicians who already have UpToDate, PubMed, and a decade of institutional knowledge.
// HQ
—
// STATUS
PRIVATE
// FOUNDED
—
// TIER
The Decacorns · $10B – $99B
// PRIMARY SECTOR
ai
// SECTORS SERVED
// TECHNOLOGY
The platform ingests peer-reviewed medical journals, clinical trial data, and treatment guidelines, then generates AI summaries and treatment recommendations structured for clinical workflows. The underlying models are likely fine-tuned variants of GPT-4 or Claude, trained on medical corpora with reinforcement learning from human feedback supplied by physician reviewers. The differentiation is supposed to be medical-grade accuracy and liability coverage — neither of which has been stress-tested in a malpractice lawsuit where the AI recommended the wrong treatment.
// WOWLS ASSESSMENT
OpenEvidence faces the oldest problem in medical software: doctors do not trust black boxes with patient outcomes, hospitals move slower than any other enterprise vertical, and FDA regulation of AI clinical tools remains undefined at commercial scale. The $12 billion valuation prices in full adoption across US hospital systems without confronting the fact that physicians have consistently rejected clinical decision support tools that feel like oversight rather than assistance. Google Health spent five years and hundreds of millions trying to sell AI diagnostics to hospitals and shut down the division in 2021 after discovering that doctors want tools that save them time, not tools that second-guess their judgment. OpenEvidence is betting that the current AI hype cycle will convince hospital administrators to purchase software their physicians did not ask for — a bet that has failed for every previous generation of medical AI.
// WHY WOWLS HUNTS THIS
Because the distance between a working medical AI demo and a tool that 10,000 physicians trust with patient care has bankrupted better-funded companies with more credible clinical validation. IBM Watson Health burned $4 billion learning that lesson.
// WOWL CONFLICT
Competes directly with WOWLS internal intelligence systems for processing medical literature and clinical data — if OpenEvidence's approach works at scale WOWLS loses a proprietary medical intelligence advantage.
// VALUATION NOTE
No public revenue figures, funding rounds, or hospital deployment numbers — valuation appears to be based on sector estimates or secondary market speculation rather than disclosed funding rounds.
VERDICT: NARRATIVE ENGINE — A $12 billion valuation with no public revenue figures, no named hospital deployments at scale, and a product category that every previous generation of medical AI has failed to commercialize outside pilot programs that never converted to enterprise contracts
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track OpenEvidence.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on OpenEvidence?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN